Separate pharmaceutical treatment records from active substance destruction claims
A pharmaceutical waste file can contain both rejected-batch decisions, a matched consignment and a treatment record, yet leave a proposed active-substance destruction claim unanswered. The missing evidence may concern what the technical assessment covers, rather than whether another receipt has arrived.
This guide helps quality, EHS and reporting teams read an existing documentary pack. The fictional case starts after the responsible specialists have approved the disposition and route. It makes no product-release, waste-classification, handling, treatment or legal decision. It provides no sampling method or treatment conditions.
Write the substance claim before reviewing the file
The proposed sentence is: “All active substances in consignment C70 were destroyed.” That sentence concerns a technical outcome for the whole consignment. Keep it separate from the narrower questions of which batches were rejected, which stock was written off and what operation the receiver reports completing.
WHO’s manufacturing FAQ explains that its antibiotic guidance covers finished-product formulation and solid waste as well as liquid streams. It describes the guidance itself as non-binding. This is limited context, not a classification or applicability decision for the fictional material below. See pages 2 and 7.
All organisations, records, substances, dates and quantities below are invented. AX and AY are placeholder active substances, not real drug names. The selected pack is complete for the listed documentary events; there are no missing movements or unmatched receipts in this exercise. Nothing stipulates that the technical outcome in the proposed sentence has been established.
Preserve two quality decisions within one consignment
Q41 records rejection of finished-product batch A41, formulation F1, for a packaging-text discrepancy. It identifies AX as the active-substance placeholder and refers the stock to an already approved disposition. The note expressly makes no finding about AX destruction or its quantity for this waste review.
Q52 records rejection of batch B52, formulation F2, because specified manufacturing documentation is incomplete. It identifies AY and refers the stock to its approved disposition. Q52 likewise contains no active-substance destruction finding. The shared rejected label must not erase the two different reasons or substitute for either decision record.
Inventory entry W70 removes both batches from available stock under those decisions. Finance entry F70 records their write-off. Neither entry purports to assess treatment performance. Link each to Q41 or Q52; do not ask the reporting coordinator to reinterpret the quality decisions or calculate chemical content from the financial value.
The controlled movement schedule records 90 kg of packed material from A41 and 60 kg from B52, both after reusable-container tare. Packaging remains included. No active-substance mass is supplied. The 150 kg total is therefore a packed-material quantity in this case, not 150 kg of AX and AY.
Read the treatment statement at its stated scope
Dispatch D70 and receipt R70 both list A41 and B52 under consignment C70, with the same 90 kg and 60 kg entries. Assume the document identities and quantity links have been checked. Their agreement resolves the movement question posed here; it does not answer the separate proposed destruction sentence.
T70, issued by the fictional receiver, records completion of its named treatment operation at unit U1 on 5 July 2026 for C70’s 150 kg. Its annex lists both batches. The record contains no substance-specific destruction conclusion, performance percentage or assessment of all outputs. Its title, Certificate of Treatment, does not add those missing statements.
Supported documentary wording: “The receiver’s T70 record reports completion of the named operation for both batches in C70, totalling 150 kg of packed material.” Retain the attribution to the receiver. This desk exercise has checked the stated record relationships; it has not independently observed the operation or verified its outcome.
Compare the performance dossier and laboratory report
The pack also contains P6, a performance dossier for an earlier qualification campaign at U1. Its stated scope concerns AX in formulation F1. It does not name C70, A41 or B52, and it excludes AY and F2. It supplies no statement that the earlier assessment applies to this current consignment.
A41 shares the AX and F1 labels with P6. That is a useful starting link for the technical reviewer, but the reporting file still lacks an applicability conclusion connecting P6 to A41’s actual treatment event. B52 additionally falls outside P6’s stated substance and formulation scope. Record those as different questions rather than one missing-certificate status.
Laboratory report L70 identifies AX as its only reported analyte and S70 as one solid-residue sample associated with T70. It contains no AY result, no assessment of other outputs and no consignment-wide destruction conclusion. Keep its actual result, unit, method and limitations in the controlled technical file; this illustration supplies none for readers to interpret.
Technical review note N70 explicitly limits L70 to its stated sample and analyte. N70 also records that applying P6 to the current A41 event has not been assessed. It reaches no destruction conclusion for either active substance in C70. These are stipulated contents of the fictional specialist’s note, not analytical judgments made by the reporting team.
The result is a complete documentary treatment trail and an unresolved technical claim. Attaching P6 and L70 to T70 does not enlarge any document’s stated scope. The team can describe what each record covers while leaving the proposed whole-consignment sentence unsubstantiated by this pack. That limitation does not prove that treatment failed.
Keep packed weight out of the performance conclusion
The quantity check is 90 + 60 = 150 kg. A41 represents 90 ÷ 150 × 100 = 60% of the packed-material weight. That calculation identifies a share of this consignment’s recorded weight only. It supplies no active-substance quantity and does not validate P6’s applicability to A41.
Consequently, “60% destruction verified” is unsupported. So is “half the substances were verified” merely because L70 names one of the two placeholders. Neither a packed-weight fraction nor a count of analyte names is a treatment-performance result. No destruction percentage is calculated in this exercise.
Turn each gap into a bounded review question
For the quality custodian: confirm the exact batch identities and provide the controlled disposition references already approved for Q41 and Q52. Preserve each rejection reason. Ask whether any later authorised record changes those decisions; do not infer a change from a receiver’s certificate or a finance entry.
For the technical owner: what existing assessment, if any, connects P6’s AX/F1 scope to A41’s actual event at U1? What separate evidence addresses AY/F2 in B52? What conclusion does L70 support within its stated sample scope? Request a documented conclusion and its limits, rather than asking for a particular reassuring answer.
For the reporting owner: save the exact proposed sentence, the batch-to-consignment links, T70’s operative wording and the technical owner’s bounded response. Keep a document marked received separate from a claim marked supported. If the intended statement changes from treatment recorded to active substances destroyed, reopen the technical review question.
Check what a later clarification actually changes
Suppose a later note N71 confirms that P6’s specified assessment applies to A41’s 5 July event at U1. It names AX and F1, explicitly leaves the destruction conclusion open and excludes B52, AY/F2 and any consignment-wide outcome. This is an alternative follow-up state, not an extra fact in the original N70 pack.
N71 would close the named applicability question for A41 to the extent stated in that note. It would not supply a destruction conclusion, extend the dossier to B52 or change Q41’s original rejection reason. Update the particular claim row that changed; retain the other open questions. More precise evidence can improve the file without making its broadest sentence supportable.
Hand over a claim map rather than a single green status
The handover has four claim rows: rejected-batch decisions, stock write-off, receiver-reported treatment and the proposed active-substance outcome. Beside each, retain the exact wording, affected batches or substances, supporting record and locator, any explicit exclusion, and the authorised reviewer’s conclusion. The last row remains open in this case even though the first three have their specified records.
A second reader should be able to locate Q41 and Q52 without borrowing T70’s wording, reproduce the 150 kg packed-weight total without calling it active-substance mass, and explain why N70 leaves the destruction claim open. This tests the reporting handover. It neither authorises physical activity nor settles the underlying technical question.
For the separate task of matching dispatches, receipts and vendor totals, use the waste vendor-record guide. This case assumes those links are already complete. The waste register guide addresses stream identity and classification evidence before this claim review.
To discuss a scoped reporting-evidence handover, contact Nitium Advisory with a non-confidential outline of the records and the unresolved claim. Keep formulations and restricted quality or analytical files with their authorised custodians.
Source and limits
WHO antibiotic-manufacturing FAQ, June 2024: scope on page 2 and non-binding status on page 7.
Primary source checked 14 October 2026. The case, records, relationships and arithmetic are original teaching material. No real batch, substance, facility or treatment has been assessed. This resource provides no legal opinion, product-quality decision, laboratory interpretation, certification or independent assurance conclusion.
Comments